Technical Analysis for COLL - Collegium Pharmaceutical, Inc.

Grade Last Price % Change Price Change
grade B 24.5 2.47% 0.59
COLL closed up 2.47 percent on Friday, February 23, 2018, on 70 percent of normal volume. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation.
1 Watcher
Track This Stock
Watchlist Portfolio

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Flat
See historical COLL trend table...

Date Alert Name Type % Chg
Feb 23 MACD Bearish Signal Line Cross Bearish 0.00%
Feb 23 Hammer Candlestick Bullish 0.00%
Feb 23 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Feb 23 Wide Bands Range Expansion 0.00%
Feb 22 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 2.47%
Feb 22 Wide Bands Range Expansion 2.47%
Feb 22 Down 3 Days in a Row Weakness 2.47%
Feb 21 Stochastic Sell Signal Bearish 0.00%
Feb 21 Wide Bands Range Expansion 0.00%
Feb 21 Overbought Stochastic Strength 0.00%

Older signals for COLL ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, focuses on developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its lead product candidate is Xtampza, an abuse-deterrent, extended-release, oral formulation of oxycodone, a prescribed opioid medication. The company is also developing COL-172, an abuse-deterrent, extended-release oxymorphone for the treatment of chronic pain; COL-195, an abuse-deterrent, extended-release hydrocodone for the treatment of chronic pain; COL-196, a morphine formulation for the treatment of pain; and COL-171, a proprietary preclinical DETERx extended-release, abuse-deterrent methylphenidate formulation for the treatment of attention deficit hyperactivity disorder. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Canton, Massachusetts.
Is COLL a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 26.77
52 Week Low 7.37
Average Volume 573,302
200-Day Moving Average 13.9864
50-Day Moving Average 21.267
20-Day Moving Average 23.5295
10-Day Moving Average 24.513
Average True Range 1.7465
ADX 20.4
+DI 22.44
-DI 24.2
Chandelier Exit (Long, 3 ATRs ) 21.5005
Chandelier Exit (Short, 3 ATRs ) 24.6095
Upper Bollinger Band 26.5797
Lower Bollinger Band 20.4793
Percent B (%b) 0.66
BandWidth 25.926603
MACD Line 1.0039
MACD Signal Line 1.038
MACD Histogram -0.0341
Fundamentals Value
Market Cap 724.38 Million
Num Shares 29.6 Million
EPS -3.59
Price-to-Earnings (P/E) Ratio -6.82
Price-to-Sales 40.60
Price-to-Book 3.16
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 27.58
Resistance 3 (R3) 27.29 25.97 27.06
Resistance 2 (R2) 25.97 25.19 26.12 26.89
Resistance 1 (R1) 25.24 24.71 25.61 25.53 26.72
Pivot Point 23.92 23.92 24.11 24.07 23.92
Support 1 (S1) 23.19 23.14 23.56 23.48 22.28
Support 2 (S2) 21.87 22.66 22.02 22.11
Support 3 (S3) 21.14 21.87 21.94
Support 4 (S4) 21.43